HGF and neoplasm: Upon binding to its ligand hepatocyte growth factor (HGF), the cMET signaling pathway controls tumor cell survival and metastasis in part via activation of the PIK3CA/AKT/mTOR pathway as well as contributing to antiangiogenic therapeutic resistance via upregulation of MET expression (15–17).